GOVXW (Geovax Labs) PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GOVXW Geovax Labs Inc GOVXW
27 GF Score
Price $0.00
! 1 Warning Sign
View Full Analysis

What is Geovax Labs PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-08), Geovax Labs's share price is $0.0035. Geovax Labs's Book Value per Share for the quarter that ended in Jun. 2026 was $0.00. Hence, Geovax Labs's PB Ratio of today is .

The historical rank and industry rank for Geovax Labs's PB Ratio or its related term are showing as below:

GOVXW' s PB Ratio Range Over the Past 10 Years
Min: 0.08   Med: 1.38   Max: 20.8
Current: 2.18

During the past 13 years, Geovax Labs's highest PB Ratio was 20.80. The lowest was 0.08. And the median was 1.38.

GOVXW's PB Ratio is ranked better than
60.5% of 1228 companies
in the Biotechnology industry
Industry Median: 2.905 vs GOVXW: 2.18

During the past 12 months, Geovax Labs's average Book Value Per Share Growth Rate was -92.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -82.00% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -69.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Geovax Labs was -57.50% per year. The lowest was -82.00% per year. And the median was -64.00% per year.

Back to Basics: PB Ratio


Geovax Labs  (NAS:GOVXW) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Geovax Labs PB Ratio Related Terms


Geovax Labs PB Ratio Historical Data

* Premium members only.

The historical data trend for Geovax Labs's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs PB Ratio Chart

Geovax Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Geovax Labs Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GOVXW vs HCWB, GLMD, SXTP: PB Ratio Comparison

For the Biotechnology subindustry, Geovax Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Geovax Labs PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's PB Ratio distribution charts can be found below:

* The bar in red indicates where Geovax Labs's PB Ratio falls into.


GOVXW
27GF Score
Geovax Labs Inc GOVXW
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geovax Labs PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Geovax Labs's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2026)
=0.0035/0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Geovax Labs Business Description

Other Exchanges GOVX:USA
Address 1955 Lake Park Drive, Suite 300, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
27GF Score

Get the complete analysis for GOVXW

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price